⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Official Title: A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Study ID: NCT05891093

Conditions

Breast Cancer

Study Description

Brief Summary: This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer.

Detailed Description: This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer. A total of 766 patients with luminal-type early breast cancer who received surgery at the Fudan University Shanghai Cancer Cancer and were classified as SNF3 (proliferative) by SNF algorithm fusion clustering will be collected for this study. Before enrollment, the primary tumors of the patients were subjected to molecular typing based on H\&E slices combined with digital pathology, and subsequent enrollment could be considered if patient pathology was confirmed as SNF3 subtype.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Beijing Cancer Hospital, Beijing, Beijing, China

Chongqing Cancer Hospital, Chongqing, Chongqing, China

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China

Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China

The First Hospital of China Medical University, Shenyang, Liaoning, China

Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China

Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China

West China Hospital of Sichuan University, Chengdu, Sichuan, China

Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: